The trial may end, but the data journey continues. Post-market studies demand new ways of collecting meaningful, low-burden data.

In Phase 3 trials, flexibility is not about lowering standards. It is about designing systems that adapt without breaking.

Digital Phase 1 trials need more than technology. They need systems built for fast signals, real-time oversight, and safety-first design.

Digital tools for nutritional trials need more than structure. They need space to capture patterns, behaviours, and context.

Digital first does not mean digital only. Paper still has a quiet role in making trials more resilient, inclusive and human.

Flexibility makes digital trials more human. But it only works when the system can bend without breaking.

Reminders inform. Nudges shape behaviour. Smart trials use both - and know the difference.

Language is not a finishing touch in digital trials. It is the interface between your study and its participants. And it shapes trust more than we realise.

Participants rarely disengage all at once. It often starts slowly, in the middle stretch. This post explores how to spot it, how to respond, and how to design for it.

Designing a protocol is more than science. Every clause becomes a digital task, workflow, or alert. And if those aren’t mapped early, study tools start to buckle.

Long-term studies aren’t won at sign-up. They’re won in the quiet weeks when life gets busy, motivation dips and thoughtful design keeps participants going.

Participant Information Sheets are one of the first touchpoints in a study. If they confuse or overwhelm, trust is lost before the first task even begins.

Monitoring does not disappear in decentralised trials. It evolves. Less about binders, more about patterns, systems and conversations that still matter.

Too many fields in an eCRF slow everything down. Thoughtful restraint can reduce burden, improve data quality, and speed up your study.

Going global in a clinical trial doesn’t have to mean chaos. Alignment is more powerful than expansion - and it starts with smarter coordination.

Retention starts with respect. Well-designed apps reduce friction, guide participants clearly and help them stay on track.

Participants can engage with and withdraw from a study as they see fit. But where do we set the limits on interruptions to the study timeline? E.g. Missed data collection or product compliance?

We cannot always anticipate changes that might crop-up mid-study, but we can set the standard for a good amendment workflow. Here's how...

It's always comforting to have a point of contact - a person who knows you and that you can connect with. In trials this is hugely important in retaining trust.

Everyone has a choice in their preference of communication (or non-communication) type. How can we align participant needs with the study design when it is tech-focussed?

Working with many sites can be difficult to coordinate in any trial. Selecting ones that work well - both ways - can be tricky.

Start the ground running with willing and pre-screened participants ready to engage in research activities.

Participation in clinical trials is at risk! Let's make it more about them with tools that work more on their terms.

Human trials in the UK typically need to be greenlit by the National Health Service (NHS). Avoid delays and constant changes by checking off some of these key items

The DCT approach is not for everyone, but if you're looking to make the switch, what are the key questions you should be asking yourself?

Engagement drives compliance! How do you keep participants engaged in your human trials?

Participants should be supported during human trials - often this can be through financial incentive. Here's how to navigate this tricky ethical territory

Clinical Research Associates (CRAs) and Clinical Research Coordinators (CRCs) are essential to trial conduct - how do they make their mark?

Are you aware of clinical trial phases? The concept and purpose of phases has evolved significantly over the last century

Is anonymity always required? How do you retain participant data rights in trials?

What are the obstacles to success in your trials? 8 things you need to be aware of

The two main types of trials - Intervention and Observational. Here are the differences and what they mean for you

Both blinded and un-blinded trials need fair group allocation. Here's how you can manage proper randomization in your trials

Finding the right cohort for your trial can be difficult, but honesty and transparency are a must - Participant Information Sheet (PIS) essentials

What is the future of clinical trials process and methodology? Can DCTs help pave the way to better trials?